Last reviewed · How we verify
Bolus surfactant
Bolus surfactant is a Pulmonary surfactant replacement therapy Small molecule drug developed by Zekai Tahir Burak Women's Health Research and Education Hospital. It is currently FDA-approved for Respiratory distress syndrome in premature neonates, Meconium aspiration syndrome. Also known as: Poractant alfa.
Bolus surfactant reduces surface tension in the lungs to improve gas exchange and respiratory function in neonates with respiratory distress syndrome.
Bolus surfactant is a type of surfactant agent used to treat conditions such as Meconium Aspiration Syndrome, Premature Birth, Premature Lungs, Respiratory Distress Syndrome, and Surfactant Deficiency Syndrome Neonatal. It is administered by bolus and is classified as a surfactant agent, with synonyms including Lucinactant.
At a glance
| Generic name | Bolus surfactant |
|---|---|
| Also known as | Poractant alfa |
| Sponsor | Zekai Tahir Burak Women's Health Research and Education Hospital |
| Drug class | Pulmonary surfactant replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Neonatology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Surfactant is a naturally occurring mixture of lipids and proteins that lines the alveoli and reduces surface tension, preventing alveolar collapse during respiration. Bolus surfactant administration directly replaces deficient endogenous surfactant in premature infants whose lungs lack sufficient surfactant production, thereby improving lung compliance and oxygenation.
Approved indications
- Respiratory distress syndrome in premature neonates
- Meconium aspiration syndrome
Common side effects
- Transient oxygen desaturation
- Bradycardia
- Pulmonary hemorrhage
- Intraventricular hemorrhage
Key clinical trials
- A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (PHASE2)
- Early Bolus Surfactant Replacement Therapy Versus Standard Care in Term Neonates With Meconium Aspiration Syndrome (NA)
- Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- Study on the Effects of Different Premedication for LISA on Stress and Cerebral Tissue Oxygenation in Preterm Infants (PHASE1)
- KL₄Surfactant Treatment in Patients With ARDS (PHASE2)
- Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU) (NA)
- Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome (PHASE4)
- Does The Surfactant Administration by Aerosolization Effective? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bolus surfactant CI brief — competitive landscape report
- Bolus surfactant updates RSS · CI watch RSS
- Zekai Tahir Burak Women's Health Research and Education Hospital portfolio CI
Frequently asked questions about Bolus surfactant
What is Bolus surfactant?
How does Bolus surfactant work?
What is Bolus surfactant used for?
Who makes Bolus surfactant?
Is Bolus surfactant also known as anything else?
What drug class is Bolus surfactant in?
What development phase is Bolus surfactant in?
What are the side effects of Bolus surfactant?
Related
- Drug class: All Pulmonary surfactant replacement therapy drugs
- Manufacturer: Zekai Tahir Burak Women's Health Research and Education Hospital — full pipeline
- Therapeutic area: All drugs in Neonatology / Respiratory
- Indication: Drugs for Respiratory distress syndrome in premature neonates
- Indication: Drugs for Meconium aspiration syndrome
- Also known as: Poractant alfa
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing